Evogen and LGC License High Sensitivity Novel HyBeacons(R) PCR Probe Technology

KANSAS CITY, Mo. & WHITE MARSH, Md. & BATH, United Kingdom & TEDDINGTON, United Kingdom--(BUSINESS WIRE)--Evogen, Inc., a global molecular diagnostics company, and LGC, an international science-based company and recognised provider of laboratory services and measurement standards, announced today that they have signed a worldwide license agreement of LGC’s HyBeacons® PCR probe chemistry technology to Evogen to augment the recently launched rapid molecular diagnostics and detection platform, including the flagship instrument, the EvoCycler™ HD12. This license gives Evogen exclusive and sub-licensable rights to the HyBeacons technology within its key market areas.